RxDoctor Payments Data

Joshua Pagar, MD

Urology · Columbia, MONPI 1669679064

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 31 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$151
  • Sumitomo Pharma America, Inc.$145
  • AbbVie$132
  • C. R. Bard, Inc. & Subsidiaries$129
  • Accord Healthcare, Inc.$73
  • Ferring Pharmaceuticals Inc.$73
  • plus $303 from 9 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007 in reported general payments places this provider in the 20th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$600,518
Medicare patients
1,700
Services billed
10,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron126$82,105
TestopelTestosterone12$14,370
GemtesaVibegron20$13,507
Tamsulosin Hcl461$10,758
Finasteride243$4,443
Testosterone33$3,715
Alfuzosin Hcl ErAlfuzosin Hcl136$3,307
Trospium Chloride ErTrospium Chloride23$3,000
Tolterodine Tartrate ErTolterodine Tartrate12$2,450
Trospium Chloride40$2,354
Methenamine Hippurate11$1,696
Potassium Citrate ErPotassium Citrate17$1,590
Oxybutynin Chloride ErOxybutynin Chloride35$816
Betamethasone Dipropionate14$502
Cephalexin82$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$145$13,50720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 250 urology providers in Missouri.

Other urology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →